Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous skeletal muscle-derived cells on microcarriers is an investigational regenerative cell therapy developed by University College London through the AMELIE project for faecal incontinence, particularly following obstetric anal sphincter injury. The product consists of skeletal muscle-derived cells harvested from the individual patient, expanded ex vivo, attached to biodegradable implantable microcarriers, and injected into the damaged external anal sphincter. The microcarriers are intended to support cell delivery, survival, retention, engraftment, and subsequent skeletal-muscle regeneration to improve sphincter function and continence. ([ctis.eu](https://ctis.eu/trial/2023-504282-23-00))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous skeletal muscle-derived cells on microcarriers.